An Important Check-Up On Maravai LifeSciences Holdings Inc (NASDAQ: MRVI)

Maravai LifeSciences Holdings Inc (MRVI) concluded trading on Wednesday at a closing price of $5.03, with 3.65 million shares of worth about $18.38 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -44.85% during that period and on January 29, 2025 the price saw a loss of about -8.55%. Currently the company’s common shares owned by public are about 141.59M shares, out of which, 117.85M shares are available for trading.

Stock saw a price change of -5.45% in past 5 days and over the past one month there was a price change of -10.34%. Year-to-date (YTD), MRVI shares are showing a performance of -7.71% which decreased to -22.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.28 but also hit the highest price of $11.56 during that period. The average intraday trading volume for Maravai LifeSciences Holdings Inc shares is 2.02 million. The stock is currently trading -5.47% below its 20-day simple moving average (SMA20), while that difference is down -5.88% for SMA50 and it goes to -34.19% lower than SMA200.

Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) currently have 141.59M outstanding shares and institutions hold larger chunk of about 87.98% of that.

The stock has a current market capitalization of $1.27B and its 3Y-monthly beta is at -0.06. It has posted earnings per share of -$1.65 in the same period. It has Quick Ratio of 9.94 while making debt-to-equity ratio of 1.63. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRVI, volatility over the week remained 9.59% while standing at 8.69% over the month.

Stock’s fiscal year EPS is expected to drop by -361.30% while it is estimated to increase by 16.59% in next year.

Coverage by Goldman stated Maravai LifeSciences Holdings Inc (MRVI) stock as a Sell in their note to investors on December 05, 2024, suggesting a price target of $4.25 for the stock. Stock get an Overweight rating from Wells Fargo on August 28, 2024.

Most Popular

Related Posts